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valuating  Disability  in Inﬂammatory  Bowel Diseases:  A
tep Forward  for  Improved  Care
valiac¸ão  da  Incapacidade  na  Doenc¸a Inﬂamatória  Intestinal:
m  Passo  em  Frente  Para  um  Melhor  Tratamento
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nﬂammatory  bowel  diseases  (IBD),  which  include  Crohn’s
isease  (CD)  and  ulcerative  colitis  (UC),  are  chronic  life-
ong  diseases  that  evolve  in  a  relapsing  and  remitting  mode,
ausing  progressive  bowel  damage  over  time.  Most  epidemi-
logical  studies  show  that  there  is  a  signiﬁcant  increase  in
BD’s  incidence  in  most  regions  of  the  world.1 Being  a  chronic
ife-long  disease  with  a  young  age  at  onset,  IBD’s  prevalence
ill  likely  continue  to  increase  in  the  following  decades.  The
mpact  of  IBD  in  patients  and  society  is  of  extreme  impor-
ance,  considering  that  it  is  mainly  diagnosed  in  young  age,
ffecting  people  in  their  most  productive  years,  interfering
n  their  social,  familial  and  personal  interactions,  capac-
ty  to  acquire  education,  employment  prospects  and  work
bility.2
The  clinical  and  therapeutic  approach  to  IBD  has  been
lassically  focused  in  clinical  and  endoscopic  scores  of  gut
nﬂammation,  and  the  impact  of  disease  in  the  interaction
etween  the  individual  and  his/her  environment  (disability)
as  been  neglected  as  compared  to  other  chronic  diseases.
urthermore,  the  term  disability  in  IBD  has  been  used  in
 variable  way,  either  to  describe  disease  features  associ-
ted  with  a  worse  prognosis  (as  in  the  seminal  paper  by
eaugerie  et  al.3),  or  to  describe  speciﬁc  aspect  of  disability
such  as  work  disability),  creating  therefore  some  confu-
ion  around  what  disability  really  refers  to.  Disability  is  an
bjective  way  of  measuring  the  impairments,  activity  limita-
ions,  and  participation  restrictions  that  are  experienced  in
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ifferent  areas  or  health  domains.4 It  is  different  than  qual-
ty  of  life,  which  refers  to  the  subjective  way  the  individual
eels  about  these  limitations  and  restrictions.5 The  most
omprehensive  model  for  describing  human  functioning  in
elation  to  health  and  the  environment  is  the  Interna-
ional  Classiﬁcation  of  Functioning,  Disability  and  Health
ICF),  adopted  by  the  WHO  in  2001.4 This  model  describes
uman  functioning  in  terms  of  Body  structure,  Body  func-
ion,  Activities,  and  Participation.  It  is  applicable  to  all
eople  irrespective  of  the  health  condition  or  cultural  con-
ext,  allowing  comparison  of  health  conditions  of  different
tiology.5
The  concept  of  measuring  disability  in  IBD  has  been
ntroduced  by  Peyrin-Biroulet  and  colleagues,6 who  lead
 formal  consensus  process  that  culminated  in  the  devel-
pment  of  the  ﬁrst  tool  to  evaluate  disability  in  IBD:
he  IBD-disability  index  (IBD-DI).7 This  index  is  expected
o  capture  all  speciﬁc  aspects  of  disability  that  describe
hat  it  means  to  live  with  IBD.  For  example,  it  explores
he  limitations  felt  by  patients  in  the  areas  of  sleeping,
ood,  abdominal  pain,  defecation  regulation,  participation
n  social  and  work  events,  etc.  The  IBD-DI  is  awaiting  formal
alidation  in  prospective  cohorts  and  will  likely  become  a
idely  used  tool  in  health  reporting,  in  assessing  the  effec-
iveness  of  drugs  on  the  natural  course  of  the  disease,  and
n  appraising  the  impact  of  structural  damage  on  disability.8
In  this  issue  of  GE,  Magalhães  J  et  al.  present  the  trans-
ation  to  Portuguese  and  the  validation  in  a  Portuguese
opulation  of  the  IBD-disability  score  (IBD-DS).  The  IBD-DS
s  another  tool  that  measures  disability  in  IBD.  It  was  orig-
nally  developed  and  validated  by  Allen  et  al.  using  items
dentiﬁed  from  articles  on  disability  in  IBD,  an  expert  survey,
 by Elsevier España, S.L.U. All rights reserved.
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and  the  ICF  checklist  for  functioning  and  disability.9 In  the
original  work,  this  tool  was  found  to  be  sensitive  to  discrim-
inate  between  IBD  and  controls,  and  between  active  and
inactive  disease  in  CD,  but  not  in  UC.  A  strong  inverse  rela-
tion  was  found  between  quality  of  life  (as  measured  by  the
SIBDQ  and  SF36)  and  the  IBD-DS.9
By  translating  and  validating  the  IBD-DS  in  Portuguese
patients,  Magalhães  J  et  al.  allow  this  important  tool  to  be
available  for  every  doctor  taking  care  of  IBD  patients,  and
most  importantly,  they  introduce  the  theme  of  disability  in
our  practice.  As  we  are  moving  forward  in  our  therapeu-
tic  strategies,  targeting  at  sustained  remission  and  altering
the  natural  course  of  disease,  the  next  reasonable  step  is  to
aim  that  our  patients  live  the  most  normal  life  as  possible,
with  the  least  disability,  so  that  they  are  fully  participative
in  society  and  are  allowed  to  have  the  same  opportuni-
ties  as  others.  Although  it  is  not  anticipated  that  tools  to
measure  disability  will  be  used  in  daily  clinical  practice,
informed  clinicians  might  use  some  of  the  most  important
aspects  of  disability  in  their  patient  workups.  Indeed  many
clinicians  already  realize  the  impact  and  disability  caused
by  IBD  in  their  patients,  but  objective  ways  of  measuring
it  just  now  became  available.  Portuguese  patients  belong
to  a  different  social  and  cultural  background  and  have  a
different  health  system  organization  as  compared  to  other
populations.  Measuring  and  understanding  disability  in  the
Portuguese  population  will  allow  us  to  better  assess  the
needs  of  our  patients,  and  the  environmental  and  social
barriers  faced  by  them,  so  that  effective  interventions  are
developed.
In the  work  presented  by  Magalhães  J  et  al.,10 the  Por-
tuguese  version  of  the  IBD-DS  was  completed  by  55  CD,
and  30  UC  patients.  Similar  to  the  original  work,  the  Por-
tuguese  authors  also  found  a  signiﬁcant  negative  correlation
between  the  IBD-DS  and  the  SIBDQ.  Besides  that,  they  found
the  IBD-DS  useful  to  discriminate  disease  activity  both  in
CD  and  UC;  no  difference  in  the  mean  IBD-DS  between  CD
and  UC  was  observed.  The  authors  went  on  to  try  to  ﬁnd
predictors  of  disability  in  their  population.  Interestingly,  CD
females,  and  CD  patients  with  extra-intestinal  manifesta-
tions,  and  CD  and  UC  patients  on  a  sick  leave  or  disability
pension  presented  higher  disability  scores.  Others  have  also
correlated  these  ﬁndings  with  disability.11 Previous  history  of
hospitalization,  surgery,  perianal  disease,  disease  behaviour
and  disease  extent,  which  are  generally  considered  markers
of  bad  prognosis,  had  no  signiﬁcant  impact  in  the  IBD-DS.
However,  the  study  was  overall  slightly  underpowered,  and
the  numbers  of  patients  presenting  these  clinical  charac-
teristics  may  have  been  too  small  to  draw  any  conclusions.
Further  characterization  of  the  IBD-DS  or  any  other  validated
score  to  measure  disability  in  a  larger  Portuguese  population
are  therefore  eagerly  desired.
So  far  few  studies  assessed  disability  in  IBD,  mostly  in  a
cross-sectional  way,  and  using  slightly  different  tools.11,12
The  next  years  will  probably  bring  us  more  information
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bout  disability  measured  in  longitudinal  cohorts  and  in  spe-
iﬁc  sub-populations  of  IBD.  This  is  even  more  likely  with
he  recent  demand  from  the  FDA  to  incorporate  patient-
eported  outcomes  as  an  important  factor  in  evaluating  the
uccess  of  therapeutic  interventions.  Predictors  of  disabil-
ty  will  emerge,  the  result  of  structural  damage  on  disability,
nd  the  potential  of  drugs  or  therapeutic  strategies  to  pre-
ent  it  will  hopefully  be  identiﬁed.
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